Kathleen Moore to Enzyme Inhibitors
This is a "connection" page, showing publications Kathleen Moore has written about Enzyme Inhibitors.
Connection Strength
0.525
-
PARP inhibition in ovarian cancer: state of the science. Gynecol Oncol. 2015 Jan; 136(1):8-10.
Score: 0.430
-
A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2014 Feb; 32(1):87-93.
Score: 0.095